2023 World Conference on Lung Cancer (Posters)-P2.12. Cerebrospinal Fluid is an Alternative Medium of Liquid Biopsy for Patients with Brain Parenchymal Metastases from Non-Small Cell Lung Cancer

P2.12. Cerebrospinal Fluid is an Alternative Medium of Liquid Biopsy for Patients with Brain Parenchymal Metastases from Non-Small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

Cerebrospinal fluid (CSF) can be effectively used as a liquid biopsy for patients with brain parenchymal metastases (BPM) from non-small cell lung cancer, according to a recent study. The research aimed to determine the sensitivity of CSF in detecting mutations in patients with BPM. Eighteen advanced lung adenocarcinoma patients with BPM were enrolled in the study and had CSF and plasma samples collected for analysis. Results showed that 50% of patients had no mutations in either CSF or plasma. The most commonly mutated genes were EGFR and TP53, while CSMD3, CDKN2A, CDK6, PRKDC, FGFR3, and SMARCA4 were exclusively detected in CSF. The study concluded that CSF is a promising alternative medium for liquid biopsy in patients with BPM. The findings suggest that CSF can be used to detect genetic profiles and mutations in patients with leptomeningeal metastases. Overall, the study highlights the potential of CSF as an effective tool in monitoring and detecting mutations in patients with BPM and warrants further research and application in clinical settings.

Asset Subtitle

Jianing Chen

Meta Tag

Speaker Jianing Chen

Topic Metastatic NSCLC: Targeted Therapy - Other

Keywords

Cerebrospinal fluid

liquid biopsy

brain parenchymal metastases

non-small cell lung cancer

mutations

lung adenocarcinoma

EGFR

TP53

CSMD3

leptomeningeal metastases